Integral Diagnostics (ASX:IDX) Shares Edge Higher Today: What Are Investors Watching in the FY26 Result?

Sonal Goyal

06 November 2026 06:09 PM AEDT

Integral Diagnostics (ASX:IDX) Shares Edge Higher Today: What Are Investors Watching in the FY26 Result?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Integral Diagnostics (ASX:IDX) traded at A$1.74 during the 6 November 2026 session, up 0.58%.
FY26 Revenue and other income was A$788.7 million, up 25.6%.
Operating EBITDA was A$164.8 million, up 30.3%, with a 20.9% margin.

Integral Diagnostics (ASX:IDX) shares were quoted at A$1.74 during the 6 November 2026 trading session, up 0.58%. The S&P/ASX 200 Health Care index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. The session move is not linked to the 25 August 2026 FY26 result. Integral Diagnostics is an ASX-listed provider of diagnostic imaging services in Australia.

Latest Developments

FY26 Results (released 25 August 2026)

Integral reported revenue and other income of A$788.7 million, up 25.6%, and operating EBITDA of A$164.8 million, up 30.3%. The operating EBITDA Margin was 20.9%, up 80 basis points. The company declared a fully franked final Dividend of 6.0 cents per share, and Leverage fell to 2.3 times, in line with guidance.

About the Company

Integral Diagnostics is an ASX-listed diagnostic imaging group headquartered in East Melbourne, Victoria.

Business Overview

Integral provides imaging services such as MRI, CT and ultrasound to patients referred by doctors across its clinic network in Australia. Its Earnings depend on patient referral volumes and the mix of services.

Sector Context

The S&P/ASX 200 Health Care Index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. Diagnostic imaging providers are sensitive to Medicare rebate settings, referral patterns and equipment costs.

Risks to Watch

Imaging revenue depends on Medicare settings and patient referral volumes. Equipment, staffing and Acquisition costs can affect margins.

Catalysts on Watch

Investors may follow the H1 FY27 result, further margin progress and changes to Medicare imaging rebates.

Final Takeaways

Integral Diagnostics (ASX:IDX) traded higher on 6 November 2026 in a session where the health care index eased. Its FY26 result, released on 25 August 2026, reported strong revenue and EBITDA growth.

FAQs

Q: What was the IDX share price on 6 November 2026?

A: Integral Diagnostics shares were quoted at A$1.74 during the trading session, up 0.58%.

Q: What was FY26 revenue?

A: A$788.7 million, up 25.6%.

Q: What was operating EBITDA?

A: A$164.8 million, up 30.3%.

Q: What dividend was declared?

A: A fully franked final dividend of 6.0 cents per share.

Q: Is the session move linked to the result?

A: No. The result was released on 25 August 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.